Elutia publishes new preclinical data in Antibiotics

Elutia (ELUT) announced the publication of new preclinical data in the current issue of Antibiotics, further demonstrating the antimicrobial performance of its antibiotic-eluting biologic envelope designed to protect CIEDs from bacterial infections. The study utilized an approach to correlate in vivo and in vitro results, establishing a new tool for assessing the antimicrobial effectiveness of implantable biomaterials. Data showed rapid initial elution of antibiotics followed by more gradual elution over 14 days. Broad spectrum activity was shown across seven different Gram positive and Gram negative organisms, including Staphylococcus aureus, methicillin-resistant Staphylococcus aureus, and Staphylococcus epidermidis, with complete eradication of all tested strains. This study serves as a companion to the seminal Garrigos study published in 2024, which showed antimicrobial performance in a challenging in vivo model.